(Q42638034)

English

Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS).

scientific article published on January 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

lupus nephritis

1 reference

based on heuristic

inferred from title

David A. Isenberg

5

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Ellen M Ginzler

4

object named as

E Ginzler

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Mary Anne Dooley

3

object named as

M A Dooley

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

author name string

A Sinclair

1

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

G Appel

2

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

D Jayne

6

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

D Wofsy

7

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

N Solomons

8

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

publication date

1 January 2007

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

972-980

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Theory, targets and therapy in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084712

21 January 2018

Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084712

21 January 2018

Cyclophosphamide: new approaches for systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084712

21 January 2018

Sequential therapies for proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084712

21 January 2018

Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084712

21 January 2018

Challenges in bringing the bench to bedside in drug development for SLE.

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084712

21 January 2018

Randomized controlled trials in systemic lupus erythematosus: what has been done and what do we need to do?

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084712

21 January 2018

Biomarkers in systemic lupus erythematosus: II. Markers of disease activity

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084712

21 January 2018

Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084712

21 January 2018

Criteria for steroid-sparing ability of interventions in systemic lupus erythematosus: report of a consensus meeting

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084712

21 January 2018

New treatments for SLE: cell-depleting and anti-cytokine therapies

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084712

21 January 2018

Mycophenolate mofetil and its mechanisms of action

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084712

21 January 2018

Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide.

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084712

21 January 2018

Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084712

21 January 2018

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084712

21 January 2018

Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084712

21 January 2018

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084712

21 January 2018

The classification of glomerulonephritis in systemic lupus erythematosus revisited

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084712

21 January 2018

Membranous lupus nephritis

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084712

21 January 2018

Mycophenolate therapy of SLE membranous nephropathy

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084712

21 January 2018

Methodological issues of corticosteroid use in SLE clinical trials

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084712

21 January 2018

Clinical Trials—Multiple Treatments, Multiple End Points, and Multiple Lessons

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084712

21 January 2018

Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084712

21 January 2018

Composite outcomes in randomized trials: greater precision but with greater uncertainty?

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084712

21 January 2018

Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084712

21 January 2018

Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084712

21 January 2018

"Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis.

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084712

21 January 2018

From BILAG to BLIPS--disease activity assessment in lupus past, present and future

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084712

21 January 2018

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084712

21 January 2018

The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: Measures of overall disease activity

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084712

21 January 2018

Identifiers

10.1177/0961203307084712

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42638034&oldid=1619155892"